Prospective evaluation of a biomarker for abemaciclib-induced hepatotoxicity (confirmatory study)

Prospective evaluation of an HLA-X as a biomarker for abemaciclib-induced hepatotoxicity (confirmatory study) - Prospective evaluation of a biomarker for abemaciclib-induced hepatotoxicity (confirmatory study)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060694

Enrollment

150

Registered

2026-02-17

Start date

2026-02-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Breast cancer patients starting to treat with abemaciclib at 300 mg/day within two weeks.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To assess the association of an identified HLA allele with ALT increased of grade 2/3/4.	—

Countries

Japan

Contacts

Public ContactChiyo Imamura

Saitama Cancer Center Department of Medical Genetics and Genomics

imamura.chiyo@saitama-pho.jp048-722-1111

Outcome results